Literature DB >> 10697330

Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber. A dose-response study.

R Skripitz1, T T Andreassen, P Aspenberg.   

Abstract

Intermittent treatment with parathyroid hormone I(PTH) has an anabolic effect on both intact cancellous and cortical bone. Very little is known about the effect of the administration of PTH on the healing of fractures or the incorporation of orthopaedic implants. We have investigated the spontaneous ingrowth of callus and the formation of bone in a titanium chamber implanted at the medioproximal aspect of the tibial metaphysis of the rat. Four groups of ten male rats weighing approximately 350 g were injected with human PTH (1-34) in a dosage of 0, 15, 60 or 240 microg/kg/day, respectively, for 42 days from the day of implantation of the chamber. During the observation period the chamber became only partly filled with callus and bone and no difference in ingrowth distance into the chamber was found between the groups. The cancellous density was increased by 90%, 132% and 173% in the groups given PTH in a dosage of 15, 60 or 240 microg/kg/day, respectively. There was a linear correlation between bone density and the log PTH doses (r 2= 0.6). Our findings suggest that treatment with PTH may have a potential for enhancement of the incorporation of orthopaedic implants as well as a beneficial effect on the healing of fractures when it is given in low dosages.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10697330     DOI: 10.1302/0301-620x.82b1.9729

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  22 in total

Review 1.  [The use of bisphosphonates in arthroplasty].

Authors:  C Eberhardt; B Habermann; A A Kurth
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

Review 2.  Special Review: Accelerating fracture repair in humans: a reading of old experiments and recent clinical trials.

Authors:  Per Aspenberg
Journal:  Bonekey Rep       Date:  2013-01-09

3.  [Supportive drugs for improved implant healing].

Authors:  R Skripitz; A Kurth; A Roth
Journal:  Orthopade       Date:  2015-09       Impact factor: 1.087

4.  Do antiosteoporotic drugs improve bone regeneration in vivo?

Authors:  Maximilian Leiblein; Dirk Henrich; Florian Fervers; Kerstin Kontradowitz; Ingo Marzi; Caroline Seebach
Journal:  Eur J Trauma Emerg Surg       Date:  2019-04-26       Impact factor: 3.693

5.  A fracture does not adversely affect bone mineral density responses after teriparatide treatment.

Authors:  Aasis Unnanuntana; Quang V Ton; John P Kleimeyer; Joseph T Nguyen; Joseph M Lane
Journal:  Clin Orthop Relat Res       Date:  2011-08-24       Impact factor: 4.176

6.  Combined treatment with parathyroid hormone (1-34) and beta-tricalcium phosphate had an additive effect on local bone formation in a rat defect model.

Authors:  Zhou-Shan Tao; Kai-Kai Tu; Zheng-Liang Huang; Qiang Zhou; Tao Sun; Hong-Ming Xu; Yu-Long Zhou; Yang-Xun Lv; Wei Cui; Lei Yang
Journal:  Med Biol Eng Comput       Date:  2015-10-01       Impact factor: 2.602

Review 7.  Endogenous tissue engineering: PTH therapy for skeletal repair.

Authors:  Masahiko Takahata; Hani A Awad; Regis J O'Keefe; Susan V Bukata; Edward M Schwarz
Journal:  Cell Tissue Res       Date:  2011-05-31       Impact factor: 5.249

Review 8.  Atypical femoral fractures: a review of the literature.

Authors:  Pingal A Desai; Parth A Vyas; Joseph M Lane
Journal:  Curr Osteoporos Rep       Date:  2013-09       Impact factor: 5.096

9.  Teriparatide improves early callus formation in distal radial fractures.

Authors:  Per Aspenberg; Torsten Johansson
Journal:  Acta Orthop       Date:  2010-04       Impact factor: 3.717

10.  Parathyroid hormone PTH(1-34) increases the volume, mineral content, and mechanical properties of regenerated mineralizing tissue after distraction osteogenesis in rabbits.

Authors:  Ramune Aleksyniene; Jesper Skovhus Thomsen; Henrik Eckardt; Kristian G Bundgaard; Martin Lind; Ivan Hvid
Journal:  Acta Orthop       Date:  2009-12       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.